Personalis Inc (PSNL) Shares Soar 21.00% on Upgraded Price Target

Personalis Inc (PSNL) shares surged 21.00% today, reaching their highest level since February 2025, with an intraday gain of 23.50%.

The strategy of buying PSNL shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 7.56% annualized gain. However, the overall performance was slightly underwhelming, with a 5-year total return of 38.46%, compared to the SPY ETF's return of 41.24%. This suggests that while the strategy provided some growth, it may not have fully capitalized on broader market gains. The recent rise in quarterly testing volumes and revenue growth indicates a promising outlook for PSNL, but investors should consider these factors alongside the risks and potential for further consolidation in the biotech sector.

On May 7, 2025, H.C. Wainwright & Co. maintained its 'Buy' rating on Personalis stock and increased its price target from $8.00 to $9.00. This represents a 12.50% increase in the price target, reflecting a positive outlook on the company's future performance. This development is expected to garner attention from investors and market participants, indicating confidence in Personalis's potential to deliver returns.